Felix Behling1,2,3, Christina Fodi4,5, Marco Skardelly4,5, Frank Paulsen4,6, Ghazaleh Tabatabai4,5,7,8,9,10, Jürgen Honegger4,5, Marcos Tatagiba4,5, Jens Schittenhelm4,9,11. 1. Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany. felix.behling@med.uni-tuebingen.de. 2. Department of Neurosurgery, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Hoppe-Seyler Street 3, Tübingen, Germany. felix.behling@med.uni-tuebingen.de. 3. Hertie Institute for Clinical Brain Research, Tübingen, Germany. felix.behling@med.uni-tuebingen.de. 4. Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany. 5. Department of Neurosurgery, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Hoppe-Seyler Street 3, Tübingen, Germany. 6. Department of Radiation Oncology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany. 7. Hertie Institute for Clinical Brain Research, Tübingen, Germany. 8. Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany. 9. German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany. 10. Cluster of Excellence (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Eberhard-Karls University Tübingen, Tübingen, Germany. 11. Department of Neuropathology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Abstract
BACKGROUND: Despite best clinical management, meningioma patients experience tumor recurrence. Efforts have been made to improve the prognostic stratification of meningiomas. Recently, a multi-faceted molecular classification suggested that the marker S100 is associated with a favorable outcome, making a further analysis in a larger cohort interesting. MATERIALS AND METHODS: The immunohistochemical staining for S100 was analyzed in 1669 paraffin-embedded meningioma samples. The distribution and association with clinical data and progression-free survival via radiographic tumor recurrence were assessed. RESULTS: Of 1669 cases, 218 tumors showed strong S100 expression (13.1%). A significantly higher frequency of S100 positive meningiomas was observed in meningiomas of female patients, tumors with spinal and convexity/falx location, primary tumor surgery, NF2, higher extent of resection, lower WHO CNS grade, adjuvant radiotherapy and recurrence-free tumors during follow-up. Univariate analysis revealed a favorable progression-free survival for meningiomas with S100 expression (p = 0.0059) but not in the multivariate analysis. Higher S100 frequency was independently associated with female gender (p = 0.0003), NF2 (p < 0.0001), tumor location (p < 0.0001) and lower WHO CNS grade (p = 0.0133). CONCLUSIONS: The positive prognostic impact of S100 is mostly attributed to the confounding clinical factors gender, tumor location, NF2 status and WHO CNS grade.
BACKGROUND: Despite best clinical management, meningioma patients experience tumor recurrence. Efforts have been made to improve the prognostic stratification of meningiomas. Recently, a multi-faceted molecular classification suggested that the marker S100 is associated with a favorable outcome, making a further analysis in a larger cohort interesting. MATERIALS AND METHODS: The immunohistochemical staining for S100 was analyzed in 1669 paraffin-embedded meningioma samples. The distribution and association with clinical data and progression-free survival via radiographic tumor recurrence were assessed. RESULTS: Of 1669 cases, 218 tumors showed strong S100 expression (13.1%). A significantly higher frequency of S100 positive meningiomas was observed in meningiomas of female patients, tumors with spinal and convexity/falx location, primary tumor surgery, NF2, higher extent of resection, lower WHO CNS grade, adjuvant radiotherapy and recurrence-free tumors during follow-up. Univariate analysis revealed a favorable progression-free survival for meningiomas with S100 expression (p = 0.0059) but not in the multivariate analysis. Higher S100 frequency was independently associated with female gender (p = 0.0003), NF2 (p < 0.0001), tumor location (p < 0.0001) and lower WHO CNS grade (p = 0.0133). CONCLUSIONS: The positive prognostic impact of S100 is mostly attributed to the confounding clinical factors gender, tumor location, NF2 status and WHO CNS grade.
Authors: Sybren L N Maas; Damian Stichel; Thomas Hielscher; Philipp Sievers; Anna S Berghoff; Daniel Schrimpf; Martin Sill; Philipp Euskirchen; Christina Blume; Areeba Patel; Helin Dogan; David Reuss; Hildegard Dohmen; Marco Stein; Annekathrin Reinhardt; Abigail K Suwala; Annika K Wefers; Peter Baumgarten; Franz Ricklefs; Elisabeth J Rushing; Melanie Bewerunge-Hudler; Ralf Ketter; Jens Schittenhelm; Zane Jaunmuktane; Severina Leu; Fay E A Greenway; Leslie R Bridges; Timothy Jones; Conor Grady; Jonathan Serrano; John Golfinos; Chandra Sen; Christian Mawrin; Christine Jungk; Daniel Hänggi; Manfred Westphal; Katrin Lamszus; Nima Etminan; Gerhard Jungwirth; Christel Herold-Mende; Andreas Unterberg; Patrick N Harter; Hans-Georg Wirsching; Marian C Neidert; Miriam Ratliff; Michael Platten; Matija Snuderl; Kenneth D Aldape; Sebastian Brandner; Jürgen Hench; Stephan Frank; Stefan M Pfister; David T W Jones; Guido Reifenberger; Till Acker; Wolfgang Wick; Michael Weller; Matthias Preusser; Andreas von Deimling; Felix Sahm Journal: J Clin Oncol Date: 2021-10-07 Impact factor: 44.544
Authors: Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller Journal: Lancet Oncol Date: 2016-08-30 Impact factor: 41.316
Authors: Roland Goldbrunner; Pantelis Stavrinou; Michael D Jenkinson; Felix Sahm; Christian Mawrin; Damien C Weber; Matthias Preusser; Giuseppe Minniti; Morten Lund-Johansen; Florence Lefranc; Emanuel Houdart; Kita Sallabanda; Emilie Le Rhun; David Nieuwenhuizen; Ghazaleh Tabatabai; Riccardo Soffietti; Michael Weller Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029